Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
1998-12-07
2001-10-09
Kemmerer, Elizabeth (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C530S350000, C435S069510, C435S320100, C435S325000, C435S252300, C435S358000, C435S254200, C435S252330, C435S254110, C536S023500, C536S023100, C536S023520
Reexamination Certificate
active
06300475
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of a novel member of the family of human interferons.
BACKGROUND OF THE INVENTION
Interferons are relatively small, single-chain glycoproteins released by cells invaded by viruses or certain other substances. Interferons are presently grouped into three major classes, designated leukocyte interferon (interferon-alpha, &agr;-interferon, IFN-&agr;), fibroblast interferon (interferon-beta, &bgr;-interferon, IFN-&bgr;), and immune interferon (interferon-gamma, &ggr;-interferon, IFN-&ggr;). In response to viral infection, lymphocytes synthesize primarily &agr;-interferon (along with a lesser amount of a distinct interferon species, commonly referred to as omega interferon), while infection of fibroblasts usually induces &bgr;-interferon. &agr;- and &bgr;-interferons share about20-30percent amino acid sequence homology. Thus, the gene for human IFN-&bgr; lacks introns, and encodes a protein possessing 29 % amino acid sequence identity with human IFN&agr;I, suggesting that IFN-&agr; and IFN-&bgr; genes have evolved from a common ancestor (Taniguchi et al.,
Nature
285, 547-549 (1980)). By contrast, IFN-&ggr; is not induced by viral infection, rather, is synthesized by lymphocytesin response to mitogens, and is scarcely related to the other two types of interferons in amino acid sequence. Interferons-&agr; and -&bgr; are known to induce MHC Class I antigens, while IFN-&agr; induces MHC Class I antigen expression.
A large number of distinct genes encoding different species of IFNs-&agr; have been identified. Alpha interferon species identified previously fall into two major classes, I and II, each containing a plurality of discrete proteins (Baron et al.,
Critical Reviews in Biotechnology
10, 179-190 (1990); Nagata et al.,
Nature
287,401-408 (1980); Nagata et al.,
Nature
284, 316-320 (1980); Streuli et al,
Science
209,1343-1347 Goeddel et al.,
Nature
290, 20-26 (1981); Lawn et al.,
Science
212, 1159-1162 (1981); Ullrich et al.,
J. Mol Biol.
156, 467-486 (1982); Weissmann et al.,
Phil. Trans. R. Soc. Lond. B
299, 7-28 (1982); Lund et al.,
Proc. Natl. Acad. Sci.
81, 2435-2439 (1984); Capon et al.,
Mol. Cell. Biol.
5, 768 (1985)). The various IFN-&agr; species include IFN-&agr;A (IFN-&agr;2), IFN-&agr;B, IFN-&agr;C, IFN-&agr;C1, IFN-&agr;D (IFN-&agr;1), IFN-&agr;E, IFN-&agr;F, IFN-&agr;G, IFN-&agr;H, IFN-&agr;I, IFN-&agr;J1, IFN&agr;J2, IFN-&agr;K, IFN-&agr;L, IFN-&agr;4B, IFN-&agr;5, IFN-&agr;6, IFN-&agr;74, IFN-a76 IFN&agr;4a) IFN-&agr;88, and alleles of these species. Interestingly, while only a single human IFN-&agr; gene has been unequivocally identified, bovine IFN-&bgr; is encoded by a family of five or more homologous, yet distinct genes.
Interferons were originally produced from natural sources, such as buffy coat leukocytes and fibroblast cells, optionally using known inducing agents to increase interferon production. Interferons have also been produced by recombinant DNA technology.
The cloning and expression of recombinant IFN-&agr;A (rIFN-&agr;A) was described by Goeddel et al.,
Nature
287, 411 (1980). The amino acid sequences of rIFNs-&agr;A, B, C, D, F, G, H, K and L, along with the encoding nucleotide sequences, are described by Pestka in
Archiv. Biochem. Biophys.
221, 1 (1983). The amino acid sequences and the underlying nucleotide sequences of rIFNs-&agr;E, I and J are described in British Patent Specification No. 2,079,291, published Jan. 20, 1982. Hybrids of various IFNs-&agr; are also known, and are disclosed, e.g. by Pestka et al., supra. Nagata et al.,
Nature
284, 316 (1980), described the expression of an IFN-&agr; gene, which encoded a polypeptide (in non-mature form) that differs from rIFN-&agr;D by a single amino acid at position 114. Similarly, the cloning and expression of an IFN-&agr; gene (designated as rIFN-&agr;2) yielding a polypeptide differing from rIFN-&agr;A by a single amino acid at position23, was described in European Patent Application No. 32 134, published Jul. 15, 1981.
The cloning and expression of mature rIFN-&agr; is described by Goeddel et al.,
Nucleic Acids Res.
8, 4057 (1980).
The cloning and expression of mature rIFN-&ggr; are described by Gray et al.,
Nature
295, 503 (1982).
All of the known IFNs-&agr;, -&bgr;, and -&ggr; contain multiple cysteine residues. These residues contain sulfhydryl side-chains which are capable of forming intermolecular disulfide bonds. For example, the amino acid sequence of mature recombinant rIFN-&agr;A contains cysteine residues at positions 1, 29, 98 and 138. Wetzel et al.,
Nature
289, 606 (1981), assigned intramoleculardisulfide bonds between the cysteine residues at positions 1 and 98, and between the cysteine residues at positions 29 and 138.
Antibodies specifically binding various interferons are also well known in the art. For example, anti-&agr;-interferon agonist antibodies have been reported by Tsukui et al.,
Microbiol. Immunol.
30, 1129-1139 (1986); Duarte et al.,
Interferon-Biotechnol.
4, 221-232 (1987); Barasoain et al., J. Immunol. 143, 507-512 (1989) Exley et al.,
J. Gen. Virol.
65, 2277-2280 (1984); Shearer et al.,
J. Immunol.
133, 3096-3101 (1984); Alkan et al.,
Ciba Geigy Foundation Symposium
119, 264-278(1986); Noll et al.,
Biomed. Biochim. Acta
48, 165-176 (1989); Hertzog et al.,
J. Interferon Res.
10(Suppl. 1) (1990); Kontsek et al.,
J. Interferon Res. (special issue)
327-322 (1991), and U.S. Pat. No. 4,423,147 issued Dec. 27, 1983.
Interferons have a variety of biological activities, including antiviral, immunoregulatory and antiproliferative properties, and are, therefore, of great interest as therapeutic agents in the control of cancer, and various viral diseases. Interferons have been implicated in the pathogenesis of various autoimmune diseases, such as systemic lupus erythematoses, Behcet's disease, insulin-dependent diabetes mellitus (IDDM, also referred to as type I diabetes). It has been demonstrated in a transgenic mouse model that &bgr; cell expression of IFN-&agr; can cause insulitis and IDDM, and IFN-&agr;antagonists (including antibodies) have been proposed for the treatment of IDDM (WO 93/04699, published Mar. 18,1993). Impaired IFN-&ggr; and IFN-&agr; production has been observed in multiple sclerosis (MP) patients. An acid-labile IFN-&agr; has been detected in the serum of many AIDS patients, and it has been reported that the production of IFN-&ggr; is greatly supressed in suspensions of mitogen-stimulated mononuclear cells derived from AIDS patients. For a review see, for example, Chapter 16, “The Presence and Possible Pathogenic Role of Interferons in Disease”, In:
Interferons and other Regulatory Cytokines
, Edward de Maeyer (1988, John Wilet and Sons publishers). Alpha and beta interferons have been used in the treatment of the acute viral disease herpes zoster (T. C. Merigan et al.,
N. Engl. J. Med.
298, 981-987 (1978); E. Heidemann et al.,
Onkologie
210-212 (1984)), chronic viral infections, e.g. hepatitis B infections (R. L. Knobler et al.,
Neurology
34, 1273-279 (1984); M. A. Farkkila et al.,
Act. Neurol. Sci.
87, 325-328 (1993)). rIFN&agr;-2a (Roferon®, Roche) is an injection formulation indicated in use for the treatment of hairy cell leukemia and AIDS-related Kaposi's sarcoma. Recombinant IFN-&agr;-2b (Intron® A, Schering) has been approved for the treatment of hairy cell leukemia, selected cases of condylomata acuminata, AIDS-related Kaposis's sarcoma, chronic hepatitis Non-A, Non-B/C, and chronic helatitis B infections is certain patients. IFN-&ggr;-1 b (Actimmune®, Genentech, Inc.) is commercially available for the treatment of chronic granumatous disease.
SUMMARY OF THE INVENTION
Applicants have identified a cDNA clone (designated in the present application as “DNA50960”) that encodes a novel human interferon polypeptide.
In one embodiment, the invention provides an isolated nucleic acid molecule comprising DNA having at least a 95% sequence
Chen Jian
Wood William I.
Agarwal Atulya R.
Andres Janet L.
Genentech Inc.
Kemmerer Elizabeth
LandOfFree
Interferon PRO655 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interferon PRO655, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon PRO655 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2553393